Pilot trial of verucerfont (NBI-77860) in adult females with classic congenital adrenal hyperplasia
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2015
At a glance
- Drugs Verucerfont (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 09 Feb 2015 According to a Neurocrine Biosciences media release, a full description of the study results and related data will be presented at the Endocrine Society's 97th Annual Meeting 2015.
- 22 Jan 2015 New trial record
- 10 Dec 2014 According to a Neurocrine Biosciences media release, an orphan drug status for verucerfont (NBI-77860) in classic congenital adrenal hyperplasia from the FDA has been requested.